Zenas Biopharma (ZBIO) & The Competition Head-To-Head Review

Zenas Biopharma (NASDAQ:ZBIO) is one of 422 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Zenas Biopharma to similar businesses based on the strength of its earnings, analyst recommendations, profitability, institutional ownership, dividends, valuation and risk.

Profitability

This table compares Zenas Biopharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas Biopharma	N/A	N/A	N/A
Zenas Biopharma Competitors	-14,682.20%	39.10%	-32.41%

Dividends

Zenas Biopharma pays an annual dividend of $0.05 per share and has a dividend yield of 0.6%. Zenas Biopharma pays out -1.4% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 4.5% and pay out 116.1% of their earnings in the form of a dividend.

Institutional & Insider Ownership

29.3% of shares of all “Biotechnology” companies are held by institutional investors. 22.5% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Zenas Biopharma and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zenas Biopharma	$5.00 million	N/A	-2.17
Zenas Biopharma Competitors	$154.14 million	-$11.26 million	-61.28

Zenas Biopharma’s peers have higher revenue, but lower earnings than Zenas Biopharma. Zenas Biopharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations and price targets for Zenas Biopharma and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas Biopharma	0	0	2	0	3.00
Zenas Biopharma Competitors	831	2270	4732	56	2.51

Zenas Biopharma presently has a consensus target price of $40.00, indicating a potential upside of 418.81%. As a group, “Biotechnology” companies have a potential upside of 50.86%. Given Zenas Biopharma’s stronger consensus rating and higher possible upside, equities analysts clearly believe Zenas Biopharma is more favorable than its peers.

Summary

Zenas Biopharma beats its peers on 7 of the 13 factors compared.

About Zenas Biopharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.